Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Långsiktig säkerhet och effekt av Odevixibat hos patienter med Alagilles syndrom (ASSERT-EXT)

20 oktober 2026 uppdaterad av: Albireo, an Ipsen Company

En öppen studie för att utvärdera den långsiktiga säkerheten och effekten av Odevixibat (A4250) hos patienter med Alagilles syndrom (ASSERT-EXT)

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

Studietyp

Interventionell

Inskrivning (Faktisk)

62

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Belgien
      • Brussels, Belgien, 1200
        • Cliniques Universitaires Saint-Luc Bruxelles
  • Frankrike
      • Bron, Frankrike, 69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille, Frankrike
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris, Frankrike, 75015
        • Hopital Necker Enfants Malades
  • Förenta staterna
    • California
      • San Diego, California, Förenta staterna, 92123
        • Rady Children's Hospital
      • San Francisco, California, Förenta staterna, 94158
        • UCSF
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, Förenta staterna, 64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park, New York, Förenta staterna, 11042
        • Northwell Health System
      • New York, New York, Förenta staterna, 10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York, New York, Förenta staterna, 10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx, New York, Förenta staterna, 10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, Förenta staterna, 97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas, Texas, Förenta staterna, 75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston, Texas, Förenta staterna, 77030
        • Texas Children's Hospital
      • San Antonio, Texas, Förenta staterna, 78215
        • Texas Liver Institute
  • Italien
      • Florence, Italien
        • AOU Meyer
      • Padova, Italien, 35128
        • Azienda Ospedale University
      • Rome, Italien, 00165
        • Ospedale Pediatrico Bambino Gesu
  • Malaysia
      • Kuala Lumpur, Malaysia, 59100
        • University of Malaya Medical Center
  • Nederländerna
      • Groningen, Nederländerna, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht, Nederländerna
        • Wilhelmina Children's Hospital UMCU Utrecht
  • Polen
      • Warsaw, Polen, 04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
  • Storbritannien
      • Birmingham, Storbritannien
        • Birmingham Women's and Children's NHS Foundation Trust
      • London, Storbritannien, SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
  • Turkiet (Türkiye)
      • Istanbul, Turkiet (Türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital
  • Tyskland
      • Berlin, Tyskland, 13353
        • Charité - Universitätsmedizin Berlin
      • Hanover, Tyskland, 30625
        • Medizinische Hochschul
      • Tübingen, Tyskland, 72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis

  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.
Läkemedel: Odevixibat

Odevixibat is a small molecule and selective inhibitor of IBAT.

Andra namn:
  • A4250

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Förändring från baslinjen vid samtidig medicinering.
Tidsram: Baslinje till vecka 12 (kohort 2).
Baslinje till vecka 12 (kohort 2).
Förändring från baslinjen i nivåer av fettlösliga vitaminer.
Tidsram: Baslinje till vecka 12 (kohort 2).
Baslinje till vecka 12 (kohort 2).
Change from baseline in pruritus
Tidsram: Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.
Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Tidsram: Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.
Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
Tidsram: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.
Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
Tidsram: Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.
Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
Tidsram: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.
Baseline to week 12 (cohort 2).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Förändring från baslinjen i serum gallsyranivåer
Tidsram: Baslinje till vecka 72 (kohort 1).
Baslinje till vecka 72 (kohort 1).
Förändring från baslinjen i serum gallsyranivåer.
Tidsram: Baslinje till och med vecka 72 (kohort 1).
Baslinje till och med vecka 72 (kohort 1).
Antal deltagare med förändring från baslinjen vid fysisk undersökning
Tidsram: Baslinje till vecka 72 (kohort 1).
Baslinje till vecka 72 (kohort 1).
Antal deltagare med förändring från baslinjen i vitala tecken
Tidsram: Baslinje till vecka 72 (kohort 1).
Baslinje till vecka 72 (kohort 1).
Förändring från baslinjen vid samtidig medicinering
Tidsram: Baslinje till vecka 72 (kohort 1).
Baslinje till vecka 72 (kohort 1).
Förändring från baslinjen i laboratorietestresultat Farmakokinetisk (PK) Cmax [Tidsram: Dag 1, Vecka 4, Vecka 8 och Vecka 12]
Tidsram: Baslinje till vecka 72 (kohort 1).
Baslinje till vecka 72 (kohort 1).
Förändring från baslinjen i plasmakoncentrationen av studieläkemedlet
Tidsram: Dag 1, vecka 4, vecka 8 och vecka 12 (kohort 1).
Dag 1, vecka 4, vecka 8 och vecka 12 (kohort 1).
Farmakodynamiska parametrar: Förändring av gallsyranivåer i serum
Tidsram: Baslinje till vecka 12 (kohort 2).
Baslinje till vecka 12 (kohort 2).
Change from baseline in patient reported and observer reported itching and scratching severity scores
Tidsram: Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.
Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
Tidsram: Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments
Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
Tidsram: Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).
Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
Tidsram: Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.
Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
Tidsram: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").
Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
Tidsram: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").
Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
Tidsram: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").
Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Tidsram: Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.
Baseline to week 72 (cohort 1).

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Albireo, an Ipsen Company

Utredare

  • Studierektor: Ipsen Medical Director, Ipsen

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 september 2021

Primärt slutförande (Beräknad)

15 februari 2027

Avslutad studie (Beräknad)

15 februari 2027

Studieregistreringsdatum

Först inskickad

13 augusti 2021

Först inskickad som uppfyllde QC-kriterierna

1 september 2021

Första postat (Faktisk)

5 september 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • A4250-015
  • 2023-509028-17-00 (Ctis)
  • 2021-000996-36 (EudraCT-nummer)
  • 2023 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Tidsram för IPD-delning

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Kriterier för IPD Sharing Access

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera